Advanced

Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer.

Ceder, Jens LU ; Bjartell, Anders LU ; Gadaleanu, Virgil; Dizeyi, Nishtman LU and Abrahamsson, Per-Anders LU (2002) In The Prostate 53(1). p.50-59
Abstract
BACKGROUND: The presence of receptor subtypes for the inhibitory peptide somatostatin in prostatic tissue has been a controversial issue with conflicting reports. To elucidate whether prostatic epithelial cells express mRNA for somatostatin receptor (SSTR) subtype 2 and 4, we have investigated the localization of SSTR2 and SSTR4 transcripts in prostatic tissues by in situ hybridization. METHODS: Nonradioactive in situ hybridization was performed with specific fluorescein-labeled SSTR2 and SSTR4 riboprobes on consecutive sections of benign prostatic hyperplasia (BPH) and prostate cancer tissues. RESULTS: We report, for the first time, tissue localization of SSTR2 and SSTR4 mRNA in BPH and malignant cells of human prostate. Hybridization... (More)
BACKGROUND: The presence of receptor subtypes for the inhibitory peptide somatostatin in prostatic tissue has been a controversial issue with conflicting reports. To elucidate whether prostatic epithelial cells express mRNA for somatostatin receptor (SSTR) subtype 2 and 4, we have investigated the localization of SSTR2 and SSTR4 transcripts in prostatic tissues by in situ hybridization. METHODS: Nonradioactive in situ hybridization was performed with specific fluorescein-labeled SSTR2 and SSTR4 riboprobes on consecutive sections of benign prostatic hyperplasia (BPH) and prostate cancer tissues. RESULTS: We report, for the first time, tissue localization of SSTR2 and SSTR4 mRNA in BPH and malignant cells of human prostate. Hybridization signals for SSTR4 mRNA transcripts were confined to the prostatic epithelium (12 of 16 BPH cases, and in 12 of 13 carcinoma cases), whereas SSTR2 transcripts were predominantly localized in the stromal compartment but also were detectable in epithelial cells in a significant number of specimens (11 of 17 BPH cases, and in 12 of 14 carcinoma cases). Furthermore, the staining intensity for SSTR2 and SSTR4 transcripts is stronger in malignant cells compared with adjacent BPH epithelium. CONCLUSION: The data presented suggest that the expression of SSTR2 and SSTR4 transcripts is up-regulated in malignant cells and that not only SSTR2 agonists, but also compounds targeting the SSTR4 subtype may have a potential role in the treatment of prostate cancer. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Gene Expression Regulation, Human, In Situ Hybridization, Male, DNA Primers, Carcinoma: pathology, RNA, Messenger: analysis, Prostatic Hyperplasia: pathology, Prostatic Neoplasms: pathology, Messenger: biosynthesis, Receptors, Somatostatin: biosynthesis, Support, Non-U.S. Gov't, Up-Regulation
in
The Prostate
volume
53
issue
1
pages
50 - 59
publisher
John Wiley & Sons
external identifiers
  • pmid:12210479
  • wos:000177756000005
  • scopus:0037106043
ISSN
0270-4137
DOI
10.1002/pros.10121
language
English
LU publication?
yes
id
0bab57ac-8d2d-437d-b50b-564b0e380db4 (old id 110372)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12210479&dopt=Abstract
date added to LUP
2007-07-23 13:29:57
date last changed
2017-05-07 04:28:46
@article{0bab57ac-8d2d-437d-b50b-564b0e380db4,
  abstract     = {BACKGROUND: The presence of receptor subtypes for the inhibitory peptide somatostatin in prostatic tissue has been a controversial issue with conflicting reports. To elucidate whether prostatic epithelial cells express mRNA for somatostatin receptor (SSTR) subtype 2 and 4, we have investigated the localization of SSTR2 and SSTR4 transcripts in prostatic tissues by in situ hybridization. METHODS: Nonradioactive in situ hybridization was performed with specific fluorescein-labeled SSTR2 and SSTR4 riboprobes on consecutive sections of benign prostatic hyperplasia (BPH) and prostate cancer tissues. RESULTS: We report, for the first time, tissue localization of SSTR2 and SSTR4 mRNA in BPH and malignant cells of human prostate. Hybridization signals for SSTR4 mRNA transcripts were confined to the prostatic epithelium (12 of 16 BPH cases, and in 12 of 13 carcinoma cases), whereas SSTR2 transcripts were predominantly localized in the stromal compartment but also were detectable in epithelial cells in a significant number of specimens (11 of 17 BPH cases, and in 12 of 14 carcinoma cases). Furthermore, the staining intensity for SSTR2 and SSTR4 transcripts is stronger in malignant cells compared with adjacent BPH epithelium. CONCLUSION: The data presented suggest that the expression of SSTR2 and SSTR4 transcripts is up-regulated in malignant cells and that not only SSTR2 agonists, but also compounds targeting the SSTR4 subtype may have a potential role in the treatment of prostate cancer.},
  author       = {Ceder, Jens and Bjartell, Anders and Gadaleanu, Virgil and Dizeyi, Nishtman and Abrahamsson, Per-Anders},
  issn         = {0270-4137},
  keyword      = {Gene Expression Regulation,Human,In Situ Hybridization,Male,DNA Primers,Carcinoma: pathology,RNA,Messenger: analysis,Prostatic Hyperplasia: pathology,Prostatic Neoplasms: pathology,Messenger: biosynthesis,Receptors,Somatostatin: biosynthesis,Support,Non-U.S. Gov't,Up-Regulation},
  language     = {eng},
  number       = {1},
  pages        = {50--59},
  publisher    = {John Wiley & Sons},
  series       = {The Prostate},
  title        = {Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer.},
  url          = {http://dx.doi.org/10.1002/pros.10121},
  volume       = {53},
  year         = {2002},
}